276 related articles for article (PubMed ID: 12452049)
21. Evaluation of tumor cell dissociation as a predictive marker of lymph node metastasis in submucosal invasive colorectal carcinoma.
Hori H; Fujimori T; Fujii S; Ichikawa K; Ohkura Y; Tomita S; Ono Y; Imura J; Kuroda Y
Dis Colon Rectum; 2005 May; 48(5):938-45. PubMed ID: 15785891
[TBL] [Abstract][Full Text] [Related]
22. [Correlation among expression of E-cadherin, beta-catenin, and cyclin D1 in breast cancers].
Yang JF; Chen SL; Liu ZH; Zhang Y
Ai Zheng; 2004 Jul; 23(7):799-802. PubMed ID: 15248915
[TBL] [Abstract][Full Text] [Related]
23. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival.
Zhou YN; Xu CP; Han B; Li M; Qiao L; Fang DC; Yang JM
World J Gastroenterol; 2002 Dec; 8(6):987-93. PubMed ID: 12439911
[TBL] [Abstract][Full Text] [Related]
24. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours.
Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
J Pathol; 2002 Feb; 196(2):154-62. PubMed ID: 11793366
[TBL] [Abstract][Full Text] [Related]
25. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
[TBL] [Abstract][Full Text] [Related]
26. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.
Chetty R; Serra S; Asa SL
Am J Surg Pathol; 2008 Mar; 32(3):413-9. PubMed ID: 18300809
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of combined expression of MUC1 and adhesion molecules in advanced gastric cancer.
Ohno T; Aihara R; Kamiyama Y; Mochiki E; Asao T; Kuwano H
Eur J Cancer; 2006 Jan; 42(2):256-63. PubMed ID: 16356709
[TBL] [Abstract][Full Text] [Related]
28. Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer.
Li YJ; Meng YX; Ji XR
Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):471-7. PubMed ID: 14599963
[TBL] [Abstract][Full Text] [Related]
29. Cadherin-catenin expression in primary colorectal cancer: a survival analysis.
Hugh TJ; Dillon SA; Taylor BA; Pignatelli M; Poston GJ; Kinsella AR
Br J Cancer; 1999 Jun; 80(7):1046-51. PubMed ID: 10362114
[TBL] [Abstract][Full Text] [Related]
30. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer.
Shun CT; Wu MS; Lin JT; Wang HP; Houng RL; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1998; 45(22):944-9. PubMed ID: 9755986
[TBL] [Abstract][Full Text] [Related]
31. alpha-, beta- and chi-catenin expression in human pancreatic cancer.
Julkunen K; Mäkinen K; Kärjä V; Kosma VM; Eskelinen M
Anticancer Res; 2003; 23(6D):5043-7. PubMed ID: 14981965
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
[TBL] [Abstract][Full Text] [Related]
33. Wnt pathway is involved in advanced gastric carcinoma.
Zhang H; Xue Y
Hepatogastroenterology; 2008; 55(84):1126-30. PubMed ID: 18705344
[TBL] [Abstract][Full Text] [Related]
34. Expression of the E-cadherin-catenin complex in lung neuroendocrine tumours.
Clavel CE; Nollet F; Berx G; Tejpar S; Nawrocki-Raby B; Kaplan HH; van Roy FM; Birembaut PL
J Pathol; 2001 May; 194(1):20-6. PubMed ID: 11329137
[TBL] [Abstract][Full Text] [Related]
35. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression.
Koseki K; Takizawa T; Koike M; Ito M; Nihei Z; Sugihara K
Cancer; 2000 Aug; 89(4):724-32. PubMed ID: 10951333
[TBL] [Abstract][Full Text] [Related]
36. Relation of E-cadherin and beta-catenin expression to pit pattern in colorectal cancer.
Kojima M; Shiokawa A; Ohike N; Tamegai Y; Kato H; Morohoshi T
Oncol Rep; 2004 Sep; 12(3):533-8. PubMed ID: 15289833
[TBL] [Abstract][Full Text] [Related]
37. Reduced alpha-catenin and E-cadherin expression in breast cancer.
Rimm DL; Sinard JH; Morrow JS
Lab Invest; 1995 May; 72(5):506-12. PubMed ID: 7745946
[TBL] [Abstract][Full Text] [Related]
38. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.
Richmond PJ; Karayiannakis AJ; Nagafuchi A; Kaisary AV; Pignatelli M
Cancer Res; 1997 Aug; 57(15):3189-93. PubMed ID: 9242448
[TBL] [Abstract][Full Text] [Related]
39. Expression of classic cadherins type I in urothelial neoplastic progression.
Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
[TBL] [Abstract][Full Text] [Related]
40. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma.
Ramasami S; Kerr KM; Chapman AD; King G; Cockburn JS; Jeffrey RR
J Pathol; 2000 Dec; 192(4):427-32. PubMed ID: 11113858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]